Ozmosi | PRT-3645 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

PRT-3645

Alternative Names: PRT-3645, PRT3645, PRT 3645
Clinical Status: Active
Latest Update: 2024-07-09
Latest Update Note: News Article

Product Description

PRT3645 is a highly potent, selective and brain penetrant CDK4/6 inhibitor that demonstrated greater than 10x brain penetration compared to approved CDK4/6 agents in preclinical models.  (Sourced from: https://preludetx.com/science/discovery-engine/prt3645-cdk4-6/)

Mechanisms of Action: CDK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Prelude Therapeutics
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PRT-3645

Countries in Clinic: Singapore, United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

  • Clinical Outcomes Reported - Prelude Therapeutics presented P0 Non-Small-Cell Lung Cancer results on 2024-04-09 for PRT-3645
  • Clinical Outcomes Reported - Prelude Therapeutics presented P0 Breast Cancer results on 2024-04-09 for PRT-3645

Highest Development Phases

Phase 1: Breast Cancer|Endometrial Cancer|Glioblastoma|Head and Neck Cancer|Mesothelioma|Non-Small-Cell Lung Cancer|Sarcoma|Squamous Cell Carcinoma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05538572

 PRT3645-01

P1

Completed

Squamous Cell Carcinoma|Endometrial Cancer|Breast Cancer|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Mesothelioma|Glioblastoma|Sarcoma

2024-06-26

21%

2024-07-03

Primary Endpoints

Recent News Events

Date

Type

Title

07/09/2024

News Article

 Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

06/03/2024

News Article

 Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

05/09/2024

News Article

 Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

04/09/2024

News Article

 Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions